Hemato Oncology Testing Market worth $4.0 billion by 2024
Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024
(firmenpresse) - Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays.
The services segment accounted for the largest share of the product & services segment in the hemato oncology testing market in 2018.
Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the hemato oncology testing market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population.
Download the PDF Brochure(at)
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877
Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment
Based on end-user, the hemato-oncology testing market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests.
North America accounted for the largest share of the hemato oncology testing market in 2018
North America accounted for the largest share of the hemato oncology testing market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period.
Some of the leading players in the hemato oncology testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).
Read More(at)
https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.09.2019 - 14:14 Uhr
Sprache: Deutsch
News-ID 598085
Anzahl Zeichen: 2876
contact information:
Contact person: Rama Sharma
Town:
Pune
Phone: 08886006441
Kategorie:
Healthcare & Medical
Typ of Press Release: Financial
type of sending: send
Diese Pressemitteilung wurde bisher 466 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Hemato Oncology Testing Market worth $4.0 billion by 2024"
steht unter der journalistisch-redaktionellen Verantwortung von
MarketsandMarkets (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
